A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors-Reference-Cited by-同舟云学术

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

Published:2024-02 Issue:2 Volume:5 Page:100619
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Beckermann Kathryn E.^ORCID,Bestvina Christine M.,El Osta Badi,Sanborn Rachel E.,Borghaei Hossein,Lammers Philip Edward,Selvaggi Giovanni,Whisenant Jennifer G.,Heimann-Nichols Ellen,Berry Lynne,Hsu Chih-Yuan,Shyr Yu,Horn Leora,Wakelee Heather

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

3. Thymic tumors and immune checkpoint inhibitors;Yokoyama;J Thorac Dis,2018

4. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC;Manegold;J Thorac Oncol,2017

5. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions;Cancers;2024-03-30